CFTR and chronic bronchitis: The mechanistic basis behind the clinical benefits of roflumilast in COPD patients, including its relative predilection for individuals with frequent exacerbations and chronic bronchitis, characteristics potentially attributable to CFTR abnormality, have remained largely undefined.